Envudeucitinibum is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases[1][2].
Molecular Weight:
426.50
Purity:
99.56
CAS Number:
[2417135-66-9]
Formula:
C22H18D6N6O3
Target:
IFNAR,Interleukin Related,JAK
Application Notes:
MCE Product type: Isotope-Labeled Compounds
* VAT and and shipping costs not included. Errors and price changes excepted
